INOVIO PHARMACEUTICALS, INC. (INO) Form 8-K — Nov 9, 2026
Inovio Pharmaceuticals priced a public offering on November 5, 2026, selling 58,747,235 shares at $1.05 per share plus pre-funded warrants for 12,681,337 shares at $1.049 each, with Jefferies and Piper Sandler as lead underwriters. Underwriters exercised their option for 10,714,285 additional shares in full, and the offering is expected to close on or about November 9, 2026. The company expects approximately $80.5 million in net proceeds after discounts and expenses. Combined with existing cash, Inovio says the funds will support operating and capital expenses into late fourth quarter 2027.
Key figures
- Gross Proceeds
- approximately $80.5 million net proceeds (after discounts and expenses)
- Offering Price
- 1.05
- Shares Offered
- 58,747,235 shares plus pre-funded warrants for 12,681,337 shares
- Cash runway
- into late fourth quarter 2027
- Prefunded warrant price
- 1.049
- Greenshoe shares exercised
- 10714285
- Prefunded warrant exercise price
- 0.001
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.